Sarepta Therapeutics Inc. (SRPT) Given Strong-Buy Rating at WBB Securities
WBB Securities reaffirmed their strong-buy rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a research note released on Tuesday. The brokerage currently has a $60.00 price objective on the stock, up from their prior price objective of $40.00.
Other analysts have also issued research reports about the stock. Piper Jaffray Cos. reaffirmed a sell rating and set a $6.00 target price on shares of Sarepta Therapeutics in a report on Saturday, June 4th. Oppenheimer Holdings Inc. reissued a buy rating and set a $60.00 price target on shares of Sarepta Therapeutics in a research report on Sunday, July 17th. Wedbush reissued an outperform rating and set a $66.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday. SunTrust Banks Inc. raised shares of Sarepta Therapeutics to a reduce rating and lifted their price target for the stock from $4.00 to $48.00 in a research report on Tuesday. Finally, Cowen and Company raised shares of Sarepta Therapeutics from a market perform rating to an outperform rating and set a $64.00 price target on the stock in a research report on Tuesday. Two analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Sarepta Therapeutics has a consensus rating of Buy and an average target price of $51.01.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Tuesday. The firm’s market capitalization is $2.67 billion. The stock has a 50 day moving average of $28.17 and a 200-day moving average of $21.37. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $56.80.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period in the previous year, the business earned ($0.87) EPS. On average, equities research analysts anticipate that Sarepta Therapeutics will post ($4.98) earnings per share for the current year.
In related news, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the transaction, the chief executive officer now owns 76,983 shares in the company, valued at approximately $2,309,490. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 10.90% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas raised its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. bought a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $154,000. Quantitative Systematic Strategies LLC bought a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $211,000. National Planning Corp raised its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. Finally, First Allied Advisory Services Inc. raised its position in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the period. Institutional investors and hedge funds own 72.09% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.